Compounds > garenoxacin
Page last updated: 2024-09-03

garenoxacin and Respiratory Tract Infections

garenoxacin has been researched along with Respiratory Tract Infections in 13 studies

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (53.85)29.6817
2010's6 (46.15)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Inagaki, H; Kitamura, T; Komoriya, S; Kuroyanagi, J; Miyauchi, RN; Nagamochi, M; Odagiri, T; Sugimoto, Y; Takahashi, H1
Inagaki, H; Kitamura, T; Komoriya, S; Nagamochi, M; Odagiri, T; Takahashi, H1
Nakamura, M; Oda, T; Okada, E; Sawada, Y1
Tsuda, H1
Yamaguchi, K1
Fujiuchi, S; Kishino, S; Morita, K; Ohsaki, Y; Okumura, S; Takeda, H1
Nozawa, K; Tanigawara, Y; Tsuda, H1
Hatano, M; Ito, M; Kondo, S; Maruyama, Y; Miwa, T; Murono, S; Nakanishi, S; Wakisaka, N; Yoshizaki, T1
Biedenbach, DJ; Jones, RN1
Bellyou, T; Hoban, DJ; Low, DE; Nichol, KA; Palatnick, L; Zhanel, GG1
Esposito, S; Ianniello, F; Leone, S; Noviello, S1
Ambrose, PG; Bello, A; Costanzo, C; Echols, R; Gajjar, DA; Grasela, DM; Grasela, TH; Ludwig, EA; Phillips, L; Russo, R; Van Wart, S1
Fritsche, TR; Jones, RN; Sader, HS; Stilwell, MG1

Reviews

2 review(s) available for garenoxacin and Respiratory Tract Infections

ArticleYear
Maculopapular type drug eruption caused by garenoxacin mesilate hydrate: A case report and literature review.
    The Australasian journal of dermatology, 2017, Volume: 58, Issue:4

    Topics: Aged; Anti-Bacterial Agents; Drug Eruptions; Female; Fluoroquinolones; Humans; Respiratory Tract Infections

2017
[Pharmacological properties and clinical efficacy of garenoxacin mesilate hydrate (Geninax Tablet 200 mg), a quinolone antimicrobial].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2008, Volume: 132, Issue:2

    Topics: Administration, Oral; Anti-Bacterial Agents; Bacteria; Clinical Trials as Topic; Drug Resistance, Microbial; Fluoroquinolones; Humans; Otorhinolaryngologic Diseases; Respiratory Tract Infections; Tablets; Therapeutic Equivalency

2008

Trials

2 trial(s) available for garenoxacin and Respiratory Tract Infections

ArticleYear
Optimal dose finding of garenoxacin based on population pharmacokinetics/pharmacodynamics and Monte Carlo simulation.
    European journal of clinical pharmacology, 2012, Volume: 68, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Computer Simulation; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Intestinal Absorption; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Monte Carlo Method; Pharmacology, Clinical; Respiratory Tract Infections; Severity of Illness Index; Young Adult

2012
Efficacy and safety of garenoxacin in the treatment of upper respiratory tract infections.
    Auris, nasus, larynx, 2012, Volume: 39, Issue:5

    Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Laryngitis; Male; Middle Aged; Otitis Media; Pharyngitis; Respiratory Tract Infections; Sinusitis; Treatment Outcome

2012

Other Studies

9 other study(ies) available for garenoxacin and Respiratory Tract Infections

ArticleYear
Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
    Journal of medicinal chemistry, 2013, Mar-14, Volume: 56, Issue:5

    Topics: Animals; Anti-Bacterial Agents; Drug Design; Fluoroquinolones; Haemophilus influenzae; Male; Mice; Microbial Sensitivity Tests; Quinolones; Rats; Respiratory Tract Infections; Spiro Compounds; Staphylococcus aureus; Streptococcus pneumoniae

2013
Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
    Journal of medicinal chemistry, 2018, 08-23, Volume: 61, Issue:16

    Topics: Animals; Anti-Bacterial Agents; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; ERG1 Potassium Channel; Escherichia coli; Female; Humans; Macaca fascicularis; Male; Methicillin-Resistant Staphylococcus aureus; Mice, Inbred CBA; Microbial Sensitivity Tests; Pneumococcal Infections; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae

2018
[Profile of garenoxacin as respiratory quinolones (discussion)].
    The Japanese journal of antibiotics, 2008, Volume: 61, Issue:5

    Topics: Anti-Bacterial Agents; Bacteria; Clinical Trials as Topic; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Patient Compliance; Respiratory Tract Infections; Tissue Distribution

2008
Pharmacokinetics of garenoxacin in elderly patients with respiratory tract infections.
    International journal of antimicrobial agents, 2010, Volume: 35, Issue:6

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Bacterial Agents; Female; Fluoroquinolones; Humans; Male; Plasma; Respiratory Tract Infections; Time Factors

2010
Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001).
    Diagnostic microbiology and infectious disease, 2003, Volume: 45, Issue:4

    Topics: Anti-Bacterial Agents; Community-Acquired Infections; Drug Resistance, Microbial; Female; Fluoroquinolones; Haemophilus influenzae; Humans; Indoles; Male; Microbial Sensitivity Tests; Moraxella catarrhalis; North America; Quinolones; Respiratory Tract Infections; Sensitivity and Specificity; Streptococcus pneumoniae

2003
Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.
    Antimicrobial agents and chemotherapy, 2003, Volume: 47, Issue:6

    Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; Canada; Drug Resistance, Multiple, Bacterial; Erythromycin; Female; Fluoroquinolones; Humans; Indoles; Ketolides; Longitudinal Studies; Male; Microbial Sensitivity Tests; Middle Aged; Minocycline; Pneumococcal Infections; Quinolones; Respiratory Tract Infections; Streptococcus pneumoniae; Tigecycline

2003
Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
    The Journal of antimicrobial chemotherapy, 2003, Volume: 52, Issue:5

    Topics: Anti-Infective Agents; Bacterial Infections; Colony Count, Microbial; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Respiratory Tract Infections; Staphylococcus aureus; Streptococcus pyogenes; Time Factors

2003
Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
    Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Area Under Curve; Bronchitis; Community-Acquired Infections; Drug Interactions; Female; Fluoroquinolones; Food-Drug Interactions; Humans; Male; Mass Spectrometry; Middle Aged; Models, Biological; Pneumonia; Population; Reproducibility of Results; Respiratory Tract Infections; Sinusitis

2004
Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
    Diagnostic microbiology and infectious disease, 2007, Volume: 58, Issue:1

    Topics: Anti-Bacterial Agents; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Moraxella catarrhalis; Respiratory Tract Infections; Streptococcus pneumoniae

2007